分析在首发精神分裂症的临床治疗中应用帕利哌酮缓释片的临床效果  

The clinical effect of paliperidone extended-release tablets in the clinical treatment of first-episode schizophrenia

作　　者：贾赛 JIA Sai(Department of Pharmacy,Zibo Mental Health Center,Zibo 255100,China)

机构地区：[1]淄博市精神卫生中心药学部,255100

出　　处：《中国实用医药》2025年第4期127-130,共4页China Practical Medicine

摘　　要：目的分析在首发精神分裂症的临床治疗中应用帕利哌酮缓释片的临床效果。方法选择186例首发精神分裂症患者,依据患者入院时间的先后分为对照组和实验组,每组93例。对照组应用利培酮治疗,实验组应用帕利哌酮缓释片治疗。比较两组治疗前后的阳性与阴性症状量表(PANSS)评分、髓鞘碱性蛋白(MBP)及白细胞介素-1β(IL-1β)水平、社会功能缺陷筛选量表(SDSS)评分,不良反应发生情况,治疗效果。结果治疗后,两组精神病理症状评分、阳性症状评分、阴性症状评分及总分均下降,且实验组精神病理症状评分(22.46±1.17)分、阳性症状评分(8.34±1.23)分、阴性症状评分(10.12±2.35)分及总分(42.62±7.33)分低于对照组的(25.79±2.09)、(13.06±2.07)、(15.65±2.15)、(54.61±8.83)分,有统计学意义(P<0.05)。治疗后,两组MBP和IL-1β水平均下降,且实验组MBP(13.75±3.22)μg/L和IL-1β(44.76±9.24)ng/L低于对照组的(24.87±5.18)μg/L、(58.97±11.26)ng/L,有统计学意义(P<0.05)。治疗4、8周后,实验组SDSS评分分别为(8.20±1.87)、(5.15±1.23)分,低于对照组的(10.34±2.03)、(9.03±1.78)分,有统计学意义(P<0.05)。实验组不良反应发生率8.60%低于对照组的21.51%,有统计学意义(P<0.05)。实验组总有效率96.77%高于对照组的84.95%,有统计学意义(P<0.05)。结论首发精神分裂症的临床治疗中应用帕利哌酮缓释片安全性高且效果显著,能帮助患者改善症状和社会功能。Objective To analyze the clinical effect of paliperidone extended-release tablets in the clinical treatment of first-episode schizophrenia.Methods 186 patients with first-episode schizophrenia were selected and divided into a control group and an experimental group according to the time of admission,with 93 cases in each group.The control group was treated with risperidone,and the experimental group was treated with paliperidone extended-release tablets.Both groups were compared in terms of positive and negative syndrome scale(PANSS)score,myelin basic protein(MBP)and interleukin-1β(IL-1β)levels,social dysfunction scale(SDSS)score before and after treatment,occurrence of adverse reactions and treatment effects.Results After treatment,the psychopathological symptom score,positive symptom score,negative symptom score and total score decreased in both groups;in the experimental group,the psychopathological symptom score was(22.46±1.17)points,the positive symptom score was(8.34±1.23)points,the negative symptom score was(10.12±2.35)points and the total score was(42.62±7.33)points,which were lower than(25.79±2.09),(13.06±2.07)and(15.65±2.15),(54.61±8.83)points in the control group;there was statistical significance(P<0.05).After treatment,MBP and IL-1βlevels decreased in both groups;the experimental group had MBP of(13.75±3.22)μg/L and IL-1βof(44.76±9.24)ng/L,which were lower than(24.87±5.18)μg/L and(58.97±11.26)ng/L in the control group;there was statistical significance(P<0.05).After 4 and 8 weeks of treatment,SDSS scores of the experimental group were(8.20±1.87)and(5.15±1.23)points,which were lower than(10.34±2.03)and(9.03±1.78)points of the control group,and there was statistical significance(P<0.05).The incidence of adverse reactions of 8.60%in the experimental group was lower than 21.51%in the control group,and there was statistical significance(P<0.05).The total effective rate of 96.77%in the experimental group was higher than 84.95%in the control group,and there was statistical significance

关 键 词：首发精神分裂症 帕利哌酮缓释片 利培酮 不良反应 阳性与阴性症状量表评分 

分 类 号：R74[医药卫生—神经病学与精神病学]